• Small Molecules
    • Large Molecules
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

Points Of View

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Manufacturing vaccines during COVID-19

How and why CROs/CDMOs are better positioned to bridge the gap between vaccine demand and supply, safely and at speed.

Combating COVID-19 - The Oligonucleotide Way

Synthetic oligonucleotides have emerged as an important modality for diagnostics and potential therapy option for COVID-19.

Has the Age of Antisense Oligonucleotides Finally Arrived

Antisense Oligonucleotides is gaining momentum as a treatment modality to correct faulty protein expression by non-conventional means i.e., splicing modifications.

Your pre-clinical toxicology program needs a strategy

At Syngene, we have developed a roadmap across pre-IND, IND and NDA that seamlessly integrate the various pre-clinical studies — thereby accelerating the initiation of Clinical trials.

The Dedicated Center- Outsourcing Answer to the Innovation and ROI Challenge in the Biopharmaceutical Industry

Syngene’s dedicated  model is the equivalent of having access to a full-fledged pharma company, housed in a single campus with capabilities across small and large molecules.

Proactive COVID-19 testing

By identifying COVID-19 positive cases early on,  particularly those that are asymtomatic,  we can restrict further transmission of this deadly virus.

How Integrated CMC Can Help Expedite Early Phase Development of Small Molecules – A CRO Perspective

Syngene’s 7-phase integrated CMC strategy helps expedite IND/IMPD filings and FIH studies. As a result, the  typical time from clinical candidate to regulatory filing is  just 11 months.

To download, Please share your details